Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

700
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
700
Hepatitis01:25

Hepatitis

42
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

439
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
439

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026
Same author

Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.

NPJ precision oncology·2026
Same author

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026
Same author

Clinical and Safety Outcomes of Patients Admitted to Different Specialty Wards: The Prospective, Multi-center, Controlled SISIFO Study.

Journal of patient safety·2026
Same author

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Frontiers in immunology·2026
Same author

Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention.

Internal and emergency medicine·2026

Related Experiment Video

Updated: Apr 4, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.9K

Thrombosis Associated with Viral Hepatitis.

Luca Galli1, Victor E A Gerdes2, Luigina Guasti3

  • 1Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy ; Department of Medicine, Slotervaart Hospital, Amsterdam, The Netherlands.

Journal of Clinical and Translational Hepatology
|September 11, 2015
PubMed
Summary

Viral hepatitis, including cytomegalovirus (CMV) and Epstein-Barr virus (EBV), may increase the risk of venous thromboembolism (VTE) and portal vein thrombosis (PVT). Chronic liver disease also contributes to thrombosis risk through factor imbalances.

Keywords:
CytomegalovirusEpstein-Barr virusHepatitisHepatitis A, B and C virusThrombosis

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.7K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Related Experiment Videos

Last Updated: Apr 4, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.9K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.7K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Area of Science:

  • Hepatology
  • Virology
  • Thrombosis Research

Background:

  • Viral hepatitis is increasingly recognized as a potential contributor to venous thromboembolism (VTE).
  • Specific viruses like cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are implicated.
  • Chronic liver disease itself presents a prothrombotic state.

Purpose of the Study:

  • To review clinical data on the association between viral hepatitis and VTE.
  • To explore the pathogenetic mechanisms linking specific viruses (CMV, EBV, HAV, HBV, HCV) to thrombosis.
  • To discuss the role of chronic liver disease in VTE development.

Main Methods:

  • Narrative review of existing clinical data.
  • Discussion of pathogenetic roles of viral infections and chronic liver disease.
  • Analysis of contributing factors such as antiphospholipid antibodies and medication effects.

Main Results:

  • CMV is identified as a minor risk factor for VTE.
  • Fulminant infections with EBV and CMV, severe infections, and inflammatory diseases elevate thrombosis risk.
  • The role of antiphospholipid antibodies in chronic hepatitis B and C is debated.
  • Medications like interferon and eltrombopag may increase thrombotic risk in HCV patients.
  • Chronic liver disease leads to an imbalance of procoagulant and anticoagulant factors.

Conclusions:

  • Viral hepatitis, particularly CMV and EBV, can promote VTE and portal vein thrombosis (PVT).
  • Chronic liver disease creates a prothrombotic environment, increasing the risk of VTE and PVT.
  • Further research is needed to clarify the complex interplay between viral infections, liver disease, and thrombotic events.